Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $10.40 million. The enterprise value is $14.70 million.
| Market Cap | 10.40M |
| Enterprise Value | 14.70M |
Important Dates
The last earnings date was Friday, November 13, 2026, before market open.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 14.85 million shares outstanding. The number of shares has increased by 41.00% in one year.
| Current Share Class | 14.85M |
| Shares Outstanding | 14.85M |
| Shares Change (YoY) | +41.00% |
| Shares Change (QoQ) | +18.24% |
| Owned by Insiders (%) | 9.16% |
| Owned by Institutions (%) | 12.65% |
| Float | 9.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 2.80 |
| PS Ratio | 0.22 |
| Forward PS | 0.23 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.78
| Current Ratio | 0.78 |
| Quick Ratio | 0.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.17 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -20.62% |
| Return on Invested Capital (ROIC) | -79.10% |
| Return on Capital Employed (ROCE) | -84.16% |
| Weighted Average Cost of Capital (WACC) | 7.73% |
| Revenue Per Employee | $513,372 |
| Profits Per Employee | -$65,309 |
| Employee Count | 94 |
| Asset Turnover | 2.62 |
| Inventory Turnover | 3.25 |
Taxes
In the past 12 months, Biofrontera has paid $27,000 in taxes.
| Income Tax | 27,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.10% in the last 52 weeks. The beta is 0.96, so Biofrontera's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | -28.10% |
| 50-Day Moving Average | 1.03 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 33.42 |
| Average Volume (20 Days) | 182,058 |
Short Selling Information
The latest short interest is 189,627, so 1.28% of the outstanding shares have been sold short.
| Short Interest | 189,627 |
| Short Previous Month | 103,148 |
| Short % of Shares Out | 1.28% |
| Short % of Float | 1.93% |
| Short Ratio (days to cover) | 0.78 |
Income Statement
In the last 12 months, Biofrontera had revenue of $48.26 million and -$6.14 million in losses. Loss per share was -$0.48.
| Revenue | 48.26M |
| Gross Profit | 38.40M |
| Operating Income | -6.08M |
| Pretax Income | -6.11M |
| Net Income | -6.14M |
| EBITDA | -5.83M |
| EBIT | -6.08M |
| Loss Per Share | -$0.48 |
Balance Sheet
The company has $3.23 million in cash and $7.53 million in debt, with a net cash position of -$4.30 million or -$0.29 per share.
| Cash & Cash Equivalents | 3.23M |
| Total Debt | 7.53M |
| Net Cash | -4.30M |
| Net Cash Per Share | -$0.29 |
| Equity (Book Value) | -243,000 |
| Book Value Per Share | -0.01 |
| Working Capital | -3.13M |
Cash Flow
In the last 12 months, operating cash flow was -$7.93 million and capital expenditures -$3,000, giving a free cash flow of -$7.93 million.
| Operating Cash Flow | -7.93M |
| Capital Expenditures | -3,000 |
| Depreciation & Amortization | 257,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -7.93M |
| FCF Per Share | -$0.53 |
Margins
Gross margin is 79.58%, with operating and profit margins of -12.61% and -12.72%.
| Gross Margin | 79.58% |
| Operating Margin | -12.61% |
| Pretax Margin | -12.67% |
| Profit Margin | -12.72% |
| EBITDA Margin | -12.07% |
| EBIT Margin | -12.61% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -41.00% |
| Shareholder Yield | -41.00% |
| Earnings Yield | -68.94% |
| FCF Yield | -76.26% |
Analyst Forecast
The average price target for Biofrontera is $6.00, which is 757.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.00 |
| Price Target Difference | 757.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 16.49% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |